Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 1,222,336 |
|
|||||
| News | - | ||||||
| Day High | 217.73 | Low High |
|||||
| Day Low | 213.58 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Biogen Inc | BIIB | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.68 | -0.32% | 214.82 | 15:15:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 214.66 | 213.58 | 217.73 | 214.81 | 215.50 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 31,922 | 1,222,336 | US$ 215.82 | US$ 263,804,666 | - | 189.44 - 319.76 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:15:03 | 1 | US$ 214.82 | USD |
Biogen (BIIB) Options Flow Summary
Biogen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 31.22B | 145.36M | - | 9.84B | 1.16B | 7.99 | 26.89 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Biogen News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIIB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 193.34 | 218.86 | 192.75 | 204.80 | 2,055,362 | 21.48 | 11.11% |
| 1 Month | 213.09 | 218.86 | 189.44 | 201.44 | 1,340,812 | 1.73 | 0.81% |
| 3 Months | 240.88 | 246.48 | 189.44 | 215.18 | 1,324,927 | -26.06 | -10.82% |
| 6 Months | 236.13 | 268.74 | 189.44 | 228.97 | 1,186,430 | -21.31 | -9.02% |
| 1 Year | 305.785 | 319.76 | 189.44 | 251.95 | 1,102,967 | -90.97 | -29.75% |
| 3 Years | 264.38 | 468.2499 | 187.16 | 265.73 | 1,236,762 | -49.56 | -18.75% |
| 5 Years | 229.67 | 468.2499 | 187.16 | 269.61 | 1,385,108 | -14.85 | -6.47% |
Biogen Description
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. |
